Your browser does not support JavaScript! EQUI-PHAR BUTE (PHENYLBUTAZONE) PASTE [VEDCO]

Veterinary Medicine Labels  

                Current Medication Information


RxNorm Names

Out of scope

EQUI-PHAR BUTE (phenylbutazone) paste

Category DEA Schedule Marketing Status
PRESCRIPTION ANIMAL DRUG LABEL Abbreviated New Animal Drug Application
Drug Label Sections

DESCRIPTION: Phenylbutazone Paste is a synthetic, non-hormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to he compound's anti-inflammatory properties.
Chemically, Phenylbtazone Paste is 4-butyl-1,2-diphenyl-3-,5-pyrazolidinedione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones.

INDICATIONS: For the relief of inflammatory conditions associated with the musculoskeletal system in horses.

CONTRAINDICATIONS:  Use with caution in patients who have a history of drug allergy.

WARNING: Not for use in horses intended for food.

PRECAUTIONS: Stop medication at the first sign of gastrointestinal upset, jaundice or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white blood cell count, relative decrease in granulocytes, or black or tarry stools should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter-measures.In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

ADMINISTRATION AND DOSAGE: Orally - 1 to 2 g of phenylbutazone per 500 lb. of body weight daily. Do not exceed 4 g daily.

Guidelines to Successful Therapy: Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response. Response to Phenylbutazone Paste therapy is prompt, usually occurring within 24 hours. If no significant clinical effect is evident after five days, re-evaluate diagnosis and therapeutic approach.

When administering Phenylbutazone Paste, the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose. Many chronic conditions will respond to Phenylbutazone Paste therapy, but discontinuance of treatment may result in recurrence of symptoms.

STORAGE: Store at 15oC - 30oC (59o-86oF)


HOW SUPPLIED: Syringes containing 20 g of Phenylbutazone

Phenylbutazone Paste for Horses
Syringe label
Package Insert

phenylbutazone paste
Product Information
Product TypePRESCRIPTION ANIMAL DRUG LABELItem Code (Source)NDC:50989-560
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Phenylbutazone (Phenylbutazone) Phenylbutazone35.1 g  in 100 g
Product Characteristics
Color    Score    
FlavorAPPLE (Apple Flavor) Imprint Code
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:50989-560-1960 g in 1 SYRINGE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Labeler - Vedco (021634266)
Registrant - Med-Pharmex, Inc (025353699)
NameAddressID/FEIBusiness Operations
Med-Pharmex, Inc025353699manufacture

Revised: 10/2012

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services